NCT00721123 - A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

538

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.

Trial Locations (69)

852

Hong Kong

Tuenmen

1011

Lausanne

1023

Budapest

1090

Vienna

1130

Vienna

1160

Vienna

1405

Buenos Aires

1606

Sofia

1784

Sofia

3010

Bern

4032

Debrecen

4558

Maroochydore

5041

Adelaide

6008

Shenton Park

7632

Pécs

9010

Varna

10400

Bangkok

10700

Bangkok

14059

Berlin

14080

Mexico City

24576

Bad Bramstedt

25030

Besançon

31000

Chihuahua City

31048

Haifa

31096

Haifa

33100

Udine

44124

Cona (ferrara)

44620

México

44690

Guadalajara

49100

Petah Tikva

50200

Chiang Mai

50924

Cologne

53100

Siena

61231

Bad Nauheim

64239

Tel Aviv

69120

Heidelberg

72000

Le Mans

75475

Paris

75571

Paris

75679

Paris

76530

Baden-Baden

78240

San Luis Potosí City

84101

Beersheba

90127

Palermo

91056

Erlangen

91120

Jerusalem

94010

Créteil

98125

Gazzi

119074

Singapore

258499

Singapore

C1015ABO

Buenos Aires

C1428DQG

Buenos Aires

91350-200

Porto Alegre

04027-000

São Paulo

T2N 2T9

Calgary

V8V 3P9

Victoria

R3A 1M3

Winnipeg

A1A 5E8

St. John's

L7R 1E2

Burlington

L3Y 3R7

Newmarket

K1H 1A2

Ottawa

M4N 3M5

Toronto

H1T 2M4

Montreal

H2L 1S6

Montreal

G1W 4R4

Sainte-Foy

Unknown

Hong Kong

07760

Mexico City

921 01

Piešťany

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY